

CLINICAL TRIAL

MODIFICATION OF TUMOUR CLINICO-MORPHOLOGICAL CHARACTERISTICS AS THE RESULT OF PREPARATION "FLARAXIN" APPLICATION

The basis: Cancer Curing Center "PHOENIX" LLC

Executors: Dr. Anatoly Tkachenko, Dr. Viktor Shetilov, Dr. Elena. Oleynick

Generalized results of patients treatment with the application of anti-tumoral preparation FLARAXIN in CCC"PHOENIX"LLC are presented in the tables. Groups of patients with some oncologic diseases of stomach, breast, lungs and intestine were studied.

The results of patient's treatment having some courses of FLARAXIN are presented in **Table 1**. From 24 patients only one had the course of treatment initially having the diagnosis of the III-rd stage, the rest of the patients had the course of treatment having the IV-th stage of the disease.

Table 1. Results of patient's treatment with STOMACH CANCER under application of 1-3 courses of FLARAXIN and more.

Stage of tumoral process development	Treatment results (STOMACH CANCER)													
	After the 1-st course				After the 2-nd course				After 3 and more courses					
	Improvement		No changes		In general	Improvement		No changes		In general	Improvement		No changes	
Number	Abs.	%	Abs.	%		Abs.	%	Abs.	%		Abs.	%	Abs.	%
In general including 54	18	75	6	25	14	10	71	4	29	14	12	86	2	14
III stage. 4 patients	1	100	-	-	1	1	100	-	-	-	-	-	-	-
IV stage. 49 patients	17	74	6	25	13	9	69,2	4	30,8	14	12	85,5	2	14,3

According to these results it is clear, that the earlier the treatment is started, the higher the probability in final success. The patients in whom improvement began after the 1-st course had further improvement of their state. If after the 1-st course improvement was shown in 74% with one recovery, after 3 courses improvement comprised 85,5%.

The results of patients with breast disease treatment are presented in **Table 2**.

Table 2. Results of patient's treatment with BREAST CANCER under application of 1-3 courses of FLARAXIN and more.

Stage of tumoral process development	Treatment results (BREAST CANCER)													
	After the 1-st course				After the 2-nd course				After 3 and more courses					
	Improvement		No changes		In general	Improvement		No changes		In general	Improvement		No changes	
Number	Abs.	%	Abs.	%		Abs.	%	Abs.	%		Abs.	%	Abs.	%
In general including 54	36	68	17	32	44	33	75	11	25	34	26	76	8	24
III stage. 4 patients	4	100	-	-	1	1	100	-	-	1	1	100	-	-
IV stage. 49 patients	32	65,3	17	34,7	43	32	74,4	11	25,6	33	25	75,8	8	24,2

It can be said that on the III-rd stage the problem of the given disease can be solved without additional intrusion. On the IV-th stage only 65,3% of intrusion after the 1-st course in 65,7% of patients, after the 2-nd - in 74%, after the 3-rd in 75,8%.

The results of patients with lungs disease treatment are presented in Table 3.

Table 3. Results of patient's treatment with LUNG CANCER under application of 1-3 courses of FLARAXIN and more.

Stage of tumoral process development	Treatment results (LUNG CANCER)													
	After the 1-st course				After the 2-nd course				After 3 and more courses					
	Improvement		No changes		In general	Improvement		No changes		In general	Improvement		No changes	
Number	Abs.	%	Abs.	%		Abs.	%	Abs.	%		Abs.	%	Abs.	%
In general including 54	31	65	17	35	39	30	77	9	23	19	15	79	4	21
III stage. 4 patients	1	50	1	50	1	-	-	1	100	-	-	-	-	-
IV stage. 49 patients	30	65,2	16	34,8	38	30	78,9	8	21	19	15	79	4	21

The results of patients with intestine disease treatment are presented in Table 4.

Table 3. Results of patient's treatment with COLON (INTESTINE) CANCER under application of 1-3 courses of FLARAXIN and more.

Stage of tumoral process development	Treatment results (COLON (INTESTINE) CANCER)													
	After the 1-st course				After the 2-nd course				After 3 and more courses					
	Improvement		No changes		In general	Improvement		No changes		In general	Improvement		No changes	
Number	Abs.	%	Abs.	%		Abs.	%	Abs.	%		Abs.	%	Abs.	%
In general including 54	24	62	15	38	21	17	81	4	19	19	16	84	3	16
III stage. 4 patients	2	100	-	-	1	1	100	-	-	-	-	-	-	-
IV stage. 49 patients	22	59,5	15	40,5	20	16	80	4	20	19	16	84,2	3	15,8

CONCLUSION

1. Analysis of the data presented testify high anti-cancer activity of FLARAXIN, especially on early stages of oncologic process development.
2. The effectiveness of the FLARAXIN under application on III-rd and IV-th stages become apparent in essential improvement of life quality in the majority of patients and rise of life duration which is approved by numerous clinical trials.